Cancer Targeted Therapy-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Cancer Targeted Therapy-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Cancer Targeted Therapy industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Cancer Targeted Therapy 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Cancer Targeted Therapy worldwide and market share by regions, with company and product introduction, position in the Cancer Targeted Therapy market
Market status and development trend of Cancer Targeted Therapy by types and applications
Cost and profit status of Cancer Targeted Therapy, and marketing status
Market growth drivers and challenges
The report segments the global Cancer Targeted Therapy market as:
Global Cancer Targeted Therapy Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Cancer Targeted Therapy Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Tumor Antigens As Targets of Antibodies
Development of Antibodies for Clinical Purposes
Complement Dependent Cytotoxicity (CDC)
Signal Transduction Changes
Global Cancer Targeted Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Other
Global Cancer Targeted Therapy Market: Manufacturers Segment Analysis (Company and Product introduction, Cancer Targeted Therapy Sales Volume, Revenue, Price and Gross Margin):
Advaxis
Bind Therapeutics
Boehringer Ingelheim
Bristol Mayer Squibb
Celldex Therapeutics
Dendreon Corporation
Eli Lily
GalaxoSmithKline
Galena Biopharma
Genetech
ImmunoCellular Therapeutics
ImmunoGen
Inovio Pharmaceuticals
Johnson & Johnson
NeoStem Oncology
NewLink Genetics
Northwest Biotherapeutics
Merck
Novartis
Peregrine Pharmaceuticals
Pfizer
Roche
Sanofi
Seattle Genetics
Teva
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Cancer Targeted Therapy-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Cancer Targeted Therapy industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Cancer Targeted Therapy 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Cancer Targeted Therapy worldwide and market share by regions, with company and product introduction, position in the Cancer Targeted Therapy market
Market status and development trend of Cancer Targeted Therapy by types and applications
Cost and profit status of Cancer Targeted Therapy, and marketing status
Market growth drivers and challenges
The report segments the global Cancer Targeted Therapy market as:
Global Cancer Targeted Therapy Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Cancer Targeted Therapy Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Tumor Antigens As Targets of Antibodies
Development of Antibodies for Clinical Purposes
Complement Dependent Cytotoxicity (CDC)
Signal Transduction Changes
Global Cancer Targeted Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Other
Global Cancer Targeted Therapy Market: Manufacturers Segment Analysis (Company and Product introduction, Cancer Targeted Therapy Sales Volume, Revenue, Price and Gross Margin):
Advaxis
Bind Therapeutics
Boehringer Ingelheim
Bristol Mayer Squibb
Celldex Therapeutics
Dendreon Corporation
Eli Lily
GalaxoSmithKline
Galena Biopharma
Genetech
ImmunoCellular Therapeutics
ImmunoGen
Inovio Pharmaceuticals
Johnson & Johnson
NeoStem Oncology
NewLink Genetics
Northwest Biotherapeutics
Merck
Novartis
Peregrine Pharmaceuticals
Pfizer
Roche
Sanofi
Seattle Genetics
Teva
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF CANCER TARGETED THERAPY
1.1 Definition of Cancer Targeted Therapy in This Report
1.2 Commercial Types of Cancer Targeted Therapy
1.2.1 Tumor Antigens As Targets of Antibodies
1.2.2 Development of Antibodies for Clinical Purposes
1.2.3 Complement Dependent Cytotoxicity (CDC)
1.2.4 Signal Transduction Changes
1.3 Downstream Application of Cancer Targeted Therapy
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Other
1.4 Development History of Cancer Targeted Therapy
1.5 Market Status and Trend of Cancer Targeted Therapy 2013-2023
1.5.1 Global Cancer Targeted Therapy Market Status and Trend 2013-2023
1.5.2 Regional Cancer Targeted Therapy Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Cancer Targeted Therapy 2013-2017
2.2 Sales Market of Cancer Targeted Therapy by Regions
2.2.1 Sales Volume of Cancer Targeted Therapy by Regions
2.2.2 Sales Value of Cancer Targeted Therapy by Regions
2.3 Production Market of Cancer Targeted Therapy by Regions
2.4 Global Market Forecast of Cancer Targeted Therapy 2018-2023
2.4.1 Global Market Forecast of Cancer Targeted Therapy 2018-2023
2.4.2 Market Forecast of Cancer Targeted Therapy by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Cancer Targeted Therapy by Types
3.2 Sales Value of Cancer Targeted Therapy by Types
3.3 Market Forecast of Cancer Targeted Therapy by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Cancer Targeted Therapy by Downstream Industry
4.2 Global Market Forecast of Cancer Targeted Therapy by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Cancer Targeted Therapy Market Status by Countries
5.1.1 North America Cancer Targeted Therapy Sales by Countries (2013-2017)
5.1.2 North America Cancer Targeted Therapy Revenue by Countries (2013-2017)
5.1.3 United States Cancer Targeted Therapy Market Status (2013-2017)
5.1.4 Canada Cancer Targeted Therapy Market Status (2013-2017)
5.1.5 Mexico Cancer Targeted Therapy Market Status (2013-2017)
5.2 North America Cancer Targeted Therapy Market Status by Manufacturers
5.3 North America Cancer Targeted Therapy Market Status by Type (2013-2017)
5.3.1 North America Cancer Targeted Therapy Sales by Type (2013-2017)
5.3.2 North America Cancer Targeted Therapy Revenue by Type (2013-2017)
5.4 North America Cancer Targeted Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Cancer Targeted Therapy Market Status by Countries
6.1.1 Europe Cancer Targeted Therapy Sales by Countries (2013-2017)
6.1.2 Europe Cancer Targeted Therapy Revenue by Countries (2013-2017)
6.1.3 Germany Cancer Targeted Therapy Market Status (2013-2017)
6.1.4 UK Cancer Targeted Therapy Market Status (2013-2017)
6.1.5 France Cancer Targeted Therapy Market Status (2013-2017)
6.1.6 Italy Cancer Targeted Therapy Market Status (2013-2017)
6.1.7 Russia Cancer Targeted Therapy Market Status (2013-2017)
6.1.8 Spain Cancer Targeted Therapy Market Status (2013-2017)
6.1.9 Benelux Cancer Targeted Therapy Market Status (2013-2017)
6.2 Europe Cancer Targeted Therapy Market Status by Manufacturers
6.3 Europe Cancer Targeted Therapy Market Status by Type (2013-2017)
6.3.1 Europe Cancer Targeted Therapy Sales by Type (2013-2017)
6.3.2 Europe Cancer Targeted Therapy Revenue by Type (2013-2017)
6.4 Europe Cancer Targeted Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Cancer Targeted Therapy Market Status by Countries
7.1.1 Asia Pacific Cancer Targeted Therapy Sales by Countries (2013-2017)
7.1.2 Asia Pacific Cancer Targeted Therapy Revenue by Countries (2013-2017)
7.1.3 China Cancer Targeted Therapy Market Status (2013-2017)
7.1.4 Japan Cancer Targeted Therapy Market Status (2013-2017)
7.1.5 India Cancer Targeted Therapy Market Status (2013-2017)
7.1.6 Southeast Asia Cancer Targeted Therapy Market Status (2013-2017)
7.1.7 Australia Cancer Targeted Therapy Market Status (2013-2017)
7.2 Asia Pacific Cancer Targeted Therapy Market Status by Manufacturers
7.3 Asia Pacific Cancer Targeted Therapy Market Status by Type (2013-2017)
7.3.1 Asia Pacific Cancer Targeted Therapy Sales by Type (2013-2017)
7.3.2 Asia Pacific Cancer Targeted Therapy Revenue by Type (2013-2017)
7.4 Asia Pacific Cancer Targeted Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Cancer Targeted Therapy Market Status by Countries
8.1.1 Latin America Cancer Targeted Therapy Sales by Countries (2013-2017)
8.1.2 Latin America Cancer Targeted Therapy Revenue by Countries (2013-2017)
8.1.3 Brazil Cancer Targeted Therapy Market Status (2013-2017)
8.1.4 Argentina Cancer Targeted Therapy Market Status (2013-2017)
8.1.5 Colombia Cancer Targeted Therapy Market Status (2013-2017)
8.2 Latin America Cancer Targeted Therapy Market Status by Manufacturers
8.3 Latin America Cancer Targeted Therapy Market Status by Type (2013-2017)
8.3.1 Latin America Cancer Targeted Therapy Sales by Type (2013-2017)
8.3.2 Latin America Cancer Targeted Therapy Revenue by Type (2013-2017)
8.4 Latin America Cancer Targeted Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Cancer Targeted Therapy Market Status by Countries
9.1.1 Middle East and Africa Cancer Targeted Therapy Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Cancer Targeted Therapy Revenue by Countries (2013-2017)
9.1.3 Middle East Cancer Targeted Therapy Market Status (2013-2017)
9.1.4 Africa Cancer Targeted Therapy Market Status (2013-2017)
9.2 Middle East and Africa Cancer Targeted Therapy Market Status by Manufacturers
9.3 Middle East and Africa Cancer Targeted Therapy Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Cancer Targeted Therapy Sales by Type (2013-2017)
9.3.2 Middle East and Africa Cancer Targeted Therapy Revenue by Type (2013-2017)
9.4 Middle East and Africa Cancer Targeted Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF CANCER TARGETED THERAPY
10.1 Global Economy Situation and Trend Overview
10.2 Cancer Targeted Therapy Downstream Industry Situation and Trend Overview
CHAPTER 11 CANCER TARGETED THERAPY MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Cancer Targeted Therapy by Major Manufacturers
11.2 Production Value of Cancer Targeted Therapy by Major Manufacturers
11.3 Basic Information of Cancer Targeted Therapy by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Cancer Targeted Therapy Major Manufacturer
11.3.2 Employees and Revenue Level of Cancer Targeted Therapy Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 CANCER TARGETED THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Advaxis
12.1.1 Company profile
12.1.2 Representative Cancer Targeted Therapy Product
12.1.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Advaxis
12.2 Bind Therapeutics
12.2.1 Company profile
12.2.2 Representative Cancer Targeted Therapy Product
12.2.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bind Therapeutics
12.3 Boehringer Ingelheim
12.3.1 Company profile
12.3.2 Representative Cancer Targeted Therapy Product
12.3.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
12.4 Bristol Mayer Squibb
12.4.1 Company profile
12.4.2 Representative Cancer Targeted Therapy Product
12.4.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bristol Mayer Squibb
12.5 Celldex Therapeutics
12.5.1 Company profile
12.5.2 Representative Cancer Targeted Therapy Product
12.5.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Celldex Therapeutics
12.6 Dendreon Corporation
12.6.1 Company profile
12.6.2 Representative Cancer Targeted Therapy Product
12.6.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Dendreon Corporation
12.7 Eli Lily
12.7.1 Company profile
12.7.2 Representative Cancer Targeted Therapy Product
12.7.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Eli Lily
12.8 GalaxoSmithKline
12.8.1 Company profile
12.8.2 Representative Cancer Targeted Therapy Product
12.8.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of GalaxoSmithKline
12.9 Galena Biopharma
12.9.1 Company profile
12.9.2 Representative Cancer Targeted Therapy Product
12.9.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Galena Biopharma
12.10 Genetech
12.10.1 Company profile
12.10.2 Representative Cancer Targeted Therapy Product
12.10.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Genetech
12.11 ImmunoCellular Therapeutics
12.11.1 Company profile
12.11.2 Representative Cancer Targeted Therapy Product
12.11.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of ImmunoCellular Therapeutics
12.12 ImmunoGen
12.12.1 Company profile
12.12.2 Representative Cancer Targeted Therapy Product
12.12.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of ImmunoGen
12.13 Inovio Pharmaceuticals
12.13.1 Company profile
12.13.2 Representative Cancer Targeted Therapy Product
12.13.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Inovio Pharmaceuticals
12.14 Johnson & Johnson
12.14.1 Company profile
12.14.2 Representative Cancer Targeted Therapy Product
12.14.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.15 NeoStem Oncology
12.15.1 Company profile
12.15.2 Representative Cancer Targeted Therapy Product
12.15.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of NeoStem Oncology
12.16 NewLink Genetics
12.17 Northwest Biotherapeutics
12.18 Merck
12.19 Novartis
12.20 Peregrine Pharmaceuticals
12.21 Pfizer
12.22 Roche
12.23 Sanofi
12.24 Seattle Genetics
12.25 Teva
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER TARGETED THERAPY
13.1 Industry Chain of Cancer Targeted Therapy
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF CANCER TARGETED THERAPY
14.1 Cost Structure Analysis of Cancer Targeted Therapy
14.2 Raw Materials Cost Analysis of Cancer Targeted Therapy
14.3 Labor Cost Analysis of Cancer Targeted Therapy
14.4 Manufacturing Expenses Analysis of Cancer Targeted Therapy
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Cancer Targeted Therapy in This Report
1.2 Commercial Types of Cancer Targeted Therapy
1.2.1 Tumor Antigens As Targets of Antibodies
1.2.2 Development of Antibodies for Clinical Purposes
1.2.3 Complement Dependent Cytotoxicity (CDC)
1.2.4 Signal Transduction Changes
1.3 Downstream Application of Cancer Targeted Therapy
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Other
1.4 Development History of Cancer Targeted Therapy
1.5 Market Status and Trend of Cancer Targeted Therapy 2013-2023
1.5.1 Global Cancer Targeted Therapy Market Status and Trend 2013-2023
1.5.2 Regional Cancer Targeted Therapy Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Cancer Targeted Therapy 2013-2017
2.2 Sales Market of Cancer Targeted Therapy by Regions
2.2.1 Sales Volume of Cancer Targeted Therapy by Regions
2.2.2 Sales Value of Cancer Targeted Therapy by Regions
2.3 Production Market of Cancer Targeted Therapy by Regions
2.4 Global Market Forecast of Cancer Targeted Therapy 2018-2023
2.4.1 Global Market Forecast of Cancer Targeted Therapy 2018-2023
2.4.2 Market Forecast of Cancer Targeted Therapy by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Cancer Targeted Therapy by Types
3.2 Sales Value of Cancer Targeted Therapy by Types
3.3 Market Forecast of Cancer Targeted Therapy by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Cancer Targeted Therapy by Downstream Industry
4.2 Global Market Forecast of Cancer Targeted Therapy by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Cancer Targeted Therapy Market Status by Countries
5.1.1 North America Cancer Targeted Therapy Sales by Countries (2013-2017)
5.1.2 North America Cancer Targeted Therapy Revenue by Countries (2013-2017)
5.1.3 United States Cancer Targeted Therapy Market Status (2013-2017)
5.1.4 Canada Cancer Targeted Therapy Market Status (2013-2017)
5.1.5 Mexico Cancer Targeted Therapy Market Status (2013-2017)
5.2 North America Cancer Targeted Therapy Market Status by Manufacturers
5.3 North America Cancer Targeted Therapy Market Status by Type (2013-2017)
5.3.1 North America Cancer Targeted Therapy Sales by Type (2013-2017)
5.3.2 North America Cancer Targeted Therapy Revenue by Type (2013-2017)
5.4 North America Cancer Targeted Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Cancer Targeted Therapy Market Status by Countries
6.1.1 Europe Cancer Targeted Therapy Sales by Countries (2013-2017)
6.1.2 Europe Cancer Targeted Therapy Revenue by Countries (2013-2017)
6.1.3 Germany Cancer Targeted Therapy Market Status (2013-2017)
6.1.4 UK Cancer Targeted Therapy Market Status (2013-2017)
6.1.5 France Cancer Targeted Therapy Market Status (2013-2017)
6.1.6 Italy Cancer Targeted Therapy Market Status (2013-2017)
6.1.7 Russia Cancer Targeted Therapy Market Status (2013-2017)
6.1.8 Spain Cancer Targeted Therapy Market Status (2013-2017)
6.1.9 Benelux Cancer Targeted Therapy Market Status (2013-2017)
6.2 Europe Cancer Targeted Therapy Market Status by Manufacturers
6.3 Europe Cancer Targeted Therapy Market Status by Type (2013-2017)
6.3.1 Europe Cancer Targeted Therapy Sales by Type (2013-2017)
6.3.2 Europe Cancer Targeted Therapy Revenue by Type (2013-2017)
6.4 Europe Cancer Targeted Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Cancer Targeted Therapy Market Status by Countries
7.1.1 Asia Pacific Cancer Targeted Therapy Sales by Countries (2013-2017)
7.1.2 Asia Pacific Cancer Targeted Therapy Revenue by Countries (2013-2017)
7.1.3 China Cancer Targeted Therapy Market Status (2013-2017)
7.1.4 Japan Cancer Targeted Therapy Market Status (2013-2017)
7.1.5 India Cancer Targeted Therapy Market Status (2013-2017)
7.1.6 Southeast Asia Cancer Targeted Therapy Market Status (2013-2017)
7.1.7 Australia Cancer Targeted Therapy Market Status (2013-2017)
7.2 Asia Pacific Cancer Targeted Therapy Market Status by Manufacturers
7.3 Asia Pacific Cancer Targeted Therapy Market Status by Type (2013-2017)
7.3.1 Asia Pacific Cancer Targeted Therapy Sales by Type (2013-2017)
7.3.2 Asia Pacific Cancer Targeted Therapy Revenue by Type (2013-2017)
7.4 Asia Pacific Cancer Targeted Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Cancer Targeted Therapy Market Status by Countries
8.1.1 Latin America Cancer Targeted Therapy Sales by Countries (2013-2017)
8.1.2 Latin America Cancer Targeted Therapy Revenue by Countries (2013-2017)
8.1.3 Brazil Cancer Targeted Therapy Market Status (2013-2017)
8.1.4 Argentina Cancer Targeted Therapy Market Status (2013-2017)
8.1.5 Colombia Cancer Targeted Therapy Market Status (2013-2017)
8.2 Latin America Cancer Targeted Therapy Market Status by Manufacturers
8.3 Latin America Cancer Targeted Therapy Market Status by Type (2013-2017)
8.3.1 Latin America Cancer Targeted Therapy Sales by Type (2013-2017)
8.3.2 Latin America Cancer Targeted Therapy Revenue by Type (2013-2017)
8.4 Latin America Cancer Targeted Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Cancer Targeted Therapy Market Status by Countries
9.1.1 Middle East and Africa Cancer Targeted Therapy Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Cancer Targeted Therapy Revenue by Countries (2013-2017)
9.1.3 Middle East Cancer Targeted Therapy Market Status (2013-2017)
9.1.4 Africa Cancer Targeted Therapy Market Status (2013-2017)
9.2 Middle East and Africa Cancer Targeted Therapy Market Status by Manufacturers
9.3 Middle East and Africa Cancer Targeted Therapy Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Cancer Targeted Therapy Sales by Type (2013-2017)
9.3.2 Middle East and Africa Cancer Targeted Therapy Revenue by Type (2013-2017)
9.4 Middle East and Africa Cancer Targeted Therapy Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF CANCER TARGETED THERAPY
10.1 Global Economy Situation and Trend Overview
10.2 Cancer Targeted Therapy Downstream Industry Situation and Trend Overview
CHAPTER 11 CANCER TARGETED THERAPY MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Cancer Targeted Therapy by Major Manufacturers
11.2 Production Value of Cancer Targeted Therapy by Major Manufacturers
11.3 Basic Information of Cancer Targeted Therapy by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Cancer Targeted Therapy Major Manufacturer
11.3.2 Employees and Revenue Level of Cancer Targeted Therapy Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 CANCER TARGETED THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Advaxis
12.1.1 Company profile
12.1.2 Representative Cancer Targeted Therapy Product
12.1.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Advaxis
12.2 Bind Therapeutics
12.2.1 Company profile
12.2.2 Representative Cancer Targeted Therapy Product
12.2.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bind Therapeutics
12.3 Boehringer Ingelheim
12.3.1 Company profile
12.3.2 Representative Cancer Targeted Therapy Product
12.3.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
12.4 Bristol Mayer Squibb
12.4.1 Company profile
12.4.2 Representative Cancer Targeted Therapy Product
12.4.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bristol Mayer Squibb
12.5 Celldex Therapeutics
12.5.1 Company profile
12.5.2 Representative Cancer Targeted Therapy Product
12.5.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Celldex Therapeutics
12.6 Dendreon Corporation
12.6.1 Company profile
12.6.2 Representative Cancer Targeted Therapy Product
12.6.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Dendreon Corporation
12.7 Eli Lily
12.7.1 Company profile
12.7.2 Representative Cancer Targeted Therapy Product
12.7.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Eli Lily
12.8 GalaxoSmithKline
12.8.1 Company profile
12.8.2 Representative Cancer Targeted Therapy Product
12.8.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of GalaxoSmithKline
12.9 Galena Biopharma
12.9.1 Company profile
12.9.2 Representative Cancer Targeted Therapy Product
12.9.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Galena Biopharma
12.10 Genetech
12.10.1 Company profile
12.10.2 Representative Cancer Targeted Therapy Product
12.10.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Genetech
12.11 ImmunoCellular Therapeutics
12.11.1 Company profile
12.11.2 Representative Cancer Targeted Therapy Product
12.11.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of ImmunoCellular Therapeutics
12.12 ImmunoGen
12.12.1 Company profile
12.12.2 Representative Cancer Targeted Therapy Product
12.12.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of ImmunoGen
12.13 Inovio Pharmaceuticals
12.13.1 Company profile
12.13.2 Representative Cancer Targeted Therapy Product
12.13.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Inovio Pharmaceuticals
12.14 Johnson & Johnson
12.14.1 Company profile
12.14.2 Representative Cancer Targeted Therapy Product
12.14.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.15 NeoStem Oncology
12.15.1 Company profile
12.15.2 Representative Cancer Targeted Therapy Product
12.15.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of NeoStem Oncology
12.16 NewLink Genetics
12.17 Northwest Biotherapeutics
12.18 Merck
12.19 Novartis
12.20 Peregrine Pharmaceuticals
12.21 Pfizer
12.22 Roche
12.23 Sanofi
12.24 Seattle Genetics
12.25 Teva
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER TARGETED THERAPY
13.1 Industry Chain of Cancer Targeted Therapy
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF CANCER TARGETED THERAPY
14.1 Cost Structure Analysis of Cancer Targeted Therapy
14.2 Raw Materials Cost Analysis of Cancer Targeted Therapy
14.3 Labor Cost Analysis of Cancer Targeted Therapy
14.4 Manufacturing Expenses Analysis of Cancer Targeted Therapy
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
